RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley Acquires 1,443 Shares

RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley acquired 1,443 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was purchased at an average price of $31.18 per share, for a total transaction of $44,992.74. Following the purchase, the director now owns 1,443 shares of the company’s stock, valued at $44,992.74. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jesse Anderson Corley also recently made the following trade(s):

• On Tuesday, November 12th, Jesse Anderson Corley bought 11,111 shares of RxSight stock. The stock was purchased at an average cost of $45.37 per share, with a total value of $504,106.07.

RxSight Stock Down 2.5 %

RxSight stock opened at $30.39 on Friday. RxSight, Inc. has a 1-year low of $26.29 and a 1-year high of $66.54. The firm’s 50 day simple moving average is $38.97 and its 200 day simple moving average is $46.77.

Analysts Set New Price Targets

Several research firms have recently weighed in on RXST. UBS Group initiated coverage on RxSight in a research note on Friday, December 6th. They set a “buy” rating and a $52.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and issued a $66.00 target price on shares of RxSight in a research note on Monday, January 13th. Wells Fargo & Company dropped their price target on shares of RxSight from $42.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Jefferies Financial Group began coverage on shares of RxSight in a report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price objective for the company. Finally, Stifel Nicolaus dropped their target price on RxSight from $40.00 to $35.00 and set a “hold” rating on the stock in a research report on Monday, January 13th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $58.13.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RXST. RA Capital Management L.P. grew its position in RxSight by 6.0% during the third quarter. RA Capital Management L.P. now owns 3,916,825 shares of the company’s stock worth $193,609,000 after buying an additional 222,000 shares in the last quarter. State Street Corp boosted its position in shares of RxSight by 8.3% during the 3rd quarter. State Street Corp now owns 817,671 shares of the company’s stock valued at $40,417,000 after acquiring an additional 62,349 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of RxSight by 17.7% during the third quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock worth $40,398,000 after purchasing an additional 122,775 shares in the last quarter. Driehaus Capital Management LLC increased its position in shares of RxSight by 74.9% in the second quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock worth $42,490,000 after purchasing an additional 302,367 shares during the last quarter. Finally, Brown Capital Management LLC purchased a new stake in RxSight in the third quarter valued at approximately $26,813,000. Institutional investors own 78.78% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.